Patents Assigned to Encoded Therapeutics, Inc.
  • Compositions and methods for treating laminopathies
    Patent number: 12357707
    Abstract: The present disclosure provides compositions and methods for treating, preventing, or inhibiting laminopathies. In one aspect, the disclosure provides nucleic acid constructs and/or vectors comprising a nucleotide sequence encoding lamin A and/or lamin C.
    Type: Grant
    Filed: February 28, 2020
    Date of Patent: July 15, 2025
    Assignee: Encoded Therapeutics, Inc.
    Inventors: Sirika Wood, Kartik Ramamoorthi, Stephanie Tagliatela, Anne Tanenhaus
  • High activity regulatory elements
    Patent number: 12104175
    Abstract: Provided herein are compositions and methods for driving high expression of a transgene. Compositions and methods for driving high expression of a transgene comprising one or more human-derived regulatory elements, which, when operably linked to a transgene, can result in high expression of the transgene in one or more cell types or tissues.
    Type: Grant
    Filed: November 18, 2019
    Date of Patent: October 1, 2024
    Assignee: Encoded Therapeutics, Inc.
    Inventors: Kartik Ramamoorthi, Stephanie Tagliatela, Anne Tanenhaus, Andrew Young, Szu-Ying Chen, Chi Zhang, Stephanie Martin, David Oberkofler
  • Engineered DNA binding proteins
    Patent number: 12083188
    Abstract: Provided herein are compositions and methods of use thereof comprising a non-naturally occurring DNA binding protein that modulates expression of an endogenous gene.
    Type: Grant
    Filed: May 28, 2020
    Date of Patent: September 10, 2024
    Assignee: Encoded Therapeutics, Inc.
    Inventors: Stephanie Tagliatela, Anne Tanenhaus, Kartik Ramamoorthi, Andrew Young, David Oberkofler
  • Tissue selective transgene expression
    Patent number: 10519465
    Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: December 31, 2019
    Assignee: Encoded Therapeutics, Inc.
    Inventors: Stephanie Tagliatela, Andrew Young, Szu-Ying Chen, Kartik Ramamoorthi, David Oberkofler
  • Tissue selective transgene expression
    Patent number: 10287607
    Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 14, 2019
    Assignee: Encoded Therapeutics, Inc.
    Inventors: Stephanie Tagliatela, Andrew Young, Szu-Ying Chen, Kartik Ramamoorthi, David Oberkofler
  • Tissue selective transgene expression
    Patent number: 10287608
    Abstract: Provided herein are compositions and methods for selective expression of a transgene. Compositions and methods for selective expression of a transgene comprise one or more human regulatory elements, which, when operably linked to a transgene, can facilitate selective expression of a transgene (e.g., cell-type selective expression) in a target cell as compared to at least one or more non-target cells.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: May 14, 2019
    Assignee: Encoded Therapeutics, Inc.
    Inventors: Stephanie Tagliatela, Andrew Young, Szu-Ying Chen, Kartik Ramamoorthi, David Oberkofler